BuybackAug 13, 2026, 07:31 AM
Collegium Pharmaceutical Initiates $50M Accelerated Share Repurchase
AI Summary
Collegium Pharmaceutical announced an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock. This ASR is part of the $150 million share repurchase program authorized by its Board of Directors in July 2025, leaving $100 million remaining under the program. The company believes its current valuation does not fully reflect its business strength and future prospects, viewing the repurchase as a compelling opportunity to create long-term shareholder value. Collegium received an initial delivery of 1,556,420 shares, with final settlement expected by the fourth quarter of 2026.
Key Highlights
- Collegium Pharmaceutical entered a $50 million Accelerated Share Repurchase (ASR) agreement.
- The ASR is part of a $150 million share repurchase program authorized in July 2025.
- $100 million will remain under the share repurchase program after this ASR.
- Initial delivery of 1,556,420 shares received from Jefferies LLC.
- Initial shares based on $25.70 closing stock price on August 12, 2026.
- Final settlement of the ASR is expected by the fourth quarter of 2026.
- Company had approximately 32.5 million shares outstanding as of June 30, 2026.
Price Impact
More from COLL